Prenetics Global Ltd. (PRENW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Prenetics Global Ltd. (PRENW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Prenetics Global Ltd. ever had a stock split?
Prenetics Global Ltd. Profile
| Professional Services Industry | Industrials Sector | Sheng Wu Yeung CEO | NASDAQ (CM) Exchange | G72245114 CUSIP |
| HK Country | 98 Employees | - Last Dividend | - Last Split | 18 May 2022 IPO Date |
Overview
Prenetics Global Limited is a pioneering health sciences organization with a focus on genomics, aiming to transform the fields of prevention, early disease detection, and treatment. Established in 2007 and headquartered in Quarry Bay, Hong Kong, the company strides forward in the healthcare sector by leveraging cutting-edge genomics technology. Through its innovative approaches, Prenetics Global Limited seeks to provide actionable health insights, thereby empowering individuals to make informed decisions regarding their health and wellness. The company's efforts are geared towards reducing the burden of disease globally by implementing genomic solutions that cater to a broad spectrum of healthcare needs.
Products and Services
- CircleDNA
- Insighta Joint Venture
- ACT Genomics Holdings Company Limited Equity Interests
A flagship product of Prenetics Global Limited, CircleDNA is the prevention arm of the company, employing whole exome sequencing technology. This comprehensive consumer DNA test is designed to provide insights into various aspects of personal health and predisposition to different conditions. By analyzing a vast array of genetic markers, CircleDNA equips individuals with the knowledge required to take proactive steps towards disease prevention and health optimization.
Expanding the frontier of cancer care, Prenetics Global Limited has ventured into the development of multi-cancer early detection technologies through its joint venture, Insighta. This ambitious initiative aims to transform the landscape of cancer diagnosis by making early detection more accessible and comprehensive. Through Insighta, Prenetics is at the forefront of pioneering technologies that can significantly improve cancer survival rates by identifying the disease at its nascent stages.
Prenetics also plays a crucial role in the domain of solid tumor genomic profiling through its equity interests in ACT Genomics Holdings Company Limited. The company's involvement in ACTOnco+ underscores its commitment to advancing precision medicine. By focusing on genomic profiling of solid tumors, this collaboration facilitates tailored treatment plans that are based on the genetic makeup of an individual's cancer, thereby enhancing treatment efficacy and outcomes.
